October 14, 2024
CUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read more
CUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read moreENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read moreNRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Read moreCatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Read moreCerta Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
Read moreMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
Read moreRecruitment completes for second Phase III hypertension trial investigating GMRx2 (George Medicines)
Read moreNew Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
Read moreVAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH
Read moreTech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment
Read moreGround-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Read moreComing in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
Read moreVaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate
Read moreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read moreVaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
Read moreCerta Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Read moreFirst in-human use of OncoRes Medical’s cancer imaging technology successful
Read moreAzura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
Read moreBrandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Read moreGlyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Read moreAmaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Read moreVaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Read moreENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
Read moreENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
Read moreOpinion: It’s time to make our own supply of lifesaving drugs – Chris Nave
Read moreOpinion: Why Australia needs a national biomedical incubator – Simon Wilkins
Read moreLife science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator
Read moreGlyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Read moreGlobal Kinetics Enters Remote Monitoring Business and Appoints New U.S. Commercial Leadership
Read moreAustralian spinout eyes the clinic with a prophylactic nasal spray for Covid-19
Read morePreclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
Read moreAdelaide’s BioMed City is attracting strong clinical trial interest as its critical mass continues to grow
Read morePromising new potential treatment for leading cause of Dry Eye Disease a step closer as Azura Ophthalmics announces positive results in Phase 2 Program
Read moreIndustry-led leadership programme launched to support women into more top science and innovation roles
Read moreAzura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Read moreVaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin
Read morePolyActiva completes recruitment in key Phase I glaucoma implant safety study.
Read moreAravax reveals positive Phase I trial results at world-leading allergy conference
Read moreAustralian biotech company launched with AU$7m investment to develop therapies for treating obesity
Read moreAuspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
